Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- ChecktodayChange DetectedA government funding-related notice about potential delays and current operating status was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check7 days agoChange DetectedThe changes are cosmetic updates including a new 'Show glossary' toggle and minor label/version text adjustments that do not affect study details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page footer now shows Revision: v3.3.4, replacing Revision: v3.3.3.SummaryDifference0.1%

- Check43 days agoChange DetectedFooter now shows Revision: v3.3.3; HHS Vulnerability Disclosure link and older Revision: v3.3.2 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedMinor revision: updated from v3.2.0 to v3.3.2 and no changes to study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedRemoved the notice about government funding and potential delays. The page no longer displays operating status information.SummaryDifference0.4%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.